JC03 Rac'd PCT/PTO 06 APR 2005

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Form PTO-1390-MOD

U. S. Department of Commerce Patent and Trademark Office | ATTORNEY'S DOCKET NUMBER

6 April 2005 Date of Deposit EV 524615149 US Express Mail Label Number

(REV 1	0-96) \		DV/4-32722A/USN									
	TRANSMITTAL LETTER TO	THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)									
		40/570704										
			101920341									
	RNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED									
PCT/EP03/11377 14 October 2003 (14.10.03) 15 October 2002 (15.10.02) TITLE OF INVENTION												
METHODS TO PREDICT EDEMA AS A SIDE EFFECT OF DRUG TREATMENT												
APPLICANT(S) FOR DO/EO/US												
DRE	SSMAN ET AL.											
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:												
- 1	This is a SECOND or SUBSEQUENT su	TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EC/US) CONCERNING A FILING UNDER 35 U.S.C. 371 ATIONAL APPLICATION NO. INTERNATIONAL FILING DATE INTERNATIONAL FILING IN										
	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).											
	date.											
5.												
	b. 🔀 has been transmitted by the Inte	rnational Bureau. (See Form PC1/IB/30 n was filed in the United States Receivin	og Office (RO/US).									
	A translation of the International Applica	tion into English (35 U.S.C. 371(c)(2)).	•									
7.	Amendments to the claims of the Interna	ational Application under PCT Article 19	(35 U.S.C.371(c)(3)).									
			onal Buleauj.									
	c. have not been made; however, t	he time limit for making such amendmer	nts has NOT expired.									
8.												
	☐ An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).											
10.	0. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C.											
	37 1(c)(3)).											
ltem:	s 11. to 16. below concern document(s) o	r information included.										
11.	☐ An Information Disclosure Statement un	der 37 CFR 1.97 and 1.98.										
12. [☐ An assignment document for recording.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
13. l		A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.										
14. [An Application Data Sheet under 37 CFR 1.76.											
15. [A substitute specification.											
16. [A change of power of attorney and/or address letter.											
17. [A computer-readable form of the sequen	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.										
18. [A second copy of the published Internati	A second copy of the published International Application under 35 U.S.C. 154(d)(4).										
19. [A second copy of the English language t	A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).										
20 [Other items or information:											

JCC6 Rec'd PCT/PTO U6 APR 2009

U.S. APPLICATION NO. (if your) \$ 5373533 9 1 INTERNATIONAL APPLICATION NO. PCT/EP03/11377 DV/4-3272							2A/USN				
The following fees a								CULATIO	NS PTO USE		
							ONLY				
21. 🛛 Basic national fee											
22. Examination Fee											
☐ If Interna	ational preliminar	y examination	report was prepared by U Article 33(1)-(4)	ISPT	0	\$					
•	•										
☐ All other situations											
23. Search fee											
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international											
application to the USPTO as an International Searching Authority \$											
 ☑ If International Search Report was prepared and provided to the Office ☐ All other situations 											
-		TOTAL OF	24 22 AND 22 =				\$	900			
101AL OF 21, 22 AND 23 -											
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.											
	Extra sheets		ich additional 50 or fraction dup to a whole number)	n	RA	TE					
100 - 100 =	0 /50 =	thereof from	0		X \$	250	\$				
0	for from in bin or Abo	anth of dooles	ration later than				•	\			
Surcharge of \$130 to months from the ea							\$				
CLAIMS	NUMBE	R FILED	NUMBER EXTRA		RAT						
Total claims	31	- 20 =	11	X		50 200	\$	550 1,800			
Independent claims		-3 =	9	^	<u>\$</u>	360	\$	1,000			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360 TOTAL OF ABOVE CALCULATIONS =											
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be											
filed (Note 37 CFR 1.9, 1.27, 1.28).								3,250			
Processing fee of \$130 for furnishing the English translation later than 30 months from the									* ****		
earliest claimed priority date (37 CFR 1.492(f)).											
					IATIONA		\$	3,250			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied							\$				
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property + TOTAL FEES ENCLOSED =								3,250			
								mount to	\$		
							be:	refunded charged	\$		
a. A check in	the amount of \$		to cover the above fee	es is	enclosed			J	-		
	-					t of \$3 250 t	o cov	er the abov	e fees. A		
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$3,250 to cover the above fees. A duplicate copy of this form is enclosed.											
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a)											
or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
John T. Prince											
Novartis Attorney for Applicants Corporate Intellectual Property Reg. No. 43,019											
One Health Plaza, Building 104 (617) 871-3346											
East Hanover, NJ 07936-1080											
Date: April 6, 2005											